248 related articles for article (PubMed ID: 33496215)
1. QTc interval prolongation in patients with systemic lupus erythematosus treated with hydroxychloroquine.
Nishiyama T; Kondo Y; Tsuboi H; Noma H; Tabuchi D; Sugita T; Okamoto S; Terasaki T; Shimizu M; Honda F; Ohyama A; Kurata I; Yagishita M; Abe S; Takahashi H; Osada A; Hagiwara S; Matsumoto I; Sumida T
Mod Rheumatol; 2021 Nov; 31(6):1107-1112. PubMed ID: 33496215
[TBL] [Abstract][Full Text] [Related]
2. Evaluating the risk of QTc prolongation associated with hydroxychloroquine use with antidepressants in lupus patients with fibromyalgia.
Renaldi J; Koumpouras F; Dong X
Lupus; 2021 Oct; 30(11):1844-1848. PubMed ID: 34353174
[TBL] [Abstract][Full Text] [Related]
3. Hydroxychloroquine cardiotoxicity: a case-control study comparing patients with COVID-19 and patients with systemic lupus erythematosus.
Mancuso S; Spinelli FR; Agati L; Ciardi MR; Garufi C; Natalucci F; Molteni E; Truglia S; Riccieri V; Priori R; Mastroianni CM; Conti F
Clin Exp Rheumatol; 2022 May; 40(5):890-896. PubMed ID: 35383554
[TBL] [Abstract][Full Text] [Related]
4. Effects of hydroxychloroquine treatment on QT interval.
Hooks M; Bart B; Vardeny O; Westanmo A; Adabag S
Heart Rhythm; 2020 Nov; 17(11):1930-1935. PubMed ID: 32610165
[TBL] [Abstract][Full Text] [Related]
5. Whole blood drug levels do not correlate with QTc intervals in hydroxychloroquine-treated systemic lupus erythematosus patients.
Belmont HM; Haj-Ali M
Rheumatology (Oxford); 2022 Dec; 62(1):450-456. PubMed ID: 35426919
[TBL] [Abstract][Full Text] [Related]
6. QT prolongation associated with hydroxychloroquine and protease inhibitors in COVID-19.
Koh HM; Chong PF; Tan JN; Chidambaram SK; Chua HJ
J Clin Pharm Ther; 2021 Jun; 46(3):800-806. PubMed ID: 33768612
[TBL] [Abstract][Full Text] [Related]
7. Hydroxychloroquine/Azithromycin Therapy and QT Prolongation in Hospitalized Patients With COVID-19.
O'Connell TF; Bradley CJ; Abbas AE; Williamson BD; Rusia A; Tawney AM; Gaines R; Schott J; Dmitrienko A; Haines DE
JACC Clin Electrophysiol; 2021 Jan; 7(1):16-25. PubMed ID: 33478708
[TBL] [Abstract][Full Text] [Related]
8. Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia.
Chen CY; Wang FL; Lin CC
Clin Toxicol (Phila); 2006; 44(2):173-5. PubMed ID: 16615675
[TBL] [Abstract][Full Text] [Related]
9. Clinical impact of hydroxychloroquine dose adjustment according to the American Academy of Ophthalmology guidelines in systemic lupus erythematosus.
Vázquez-Otero I; Medina-Cintrón N; Arroyo-Ávila M; González-Sepúlveda L; Vilá LM
Lupus Sci Med; 2020 May; 7(1):. PubMed ID: 32434863
[TBL] [Abstract][Full Text] [Related]
10. QT interval parameters, anti-Ro antibody status, and disease activity in systemic lupus erythematosus.
Azharudeen M; Thabah MM; Satheesh S; Negi VS
J R Coll Physicians Edinb; 2020 Dec; 50(4):380-386. PubMed ID: 33469612
[TBL] [Abstract][Full Text] [Related]
11. Cumulative dose of hydroxychloroquine is associated with a decrease of resting heart rate in patients with systemic lupus erythematosus: a pilot study.
Cairoli E; Danese N; Teliz M; Bruzzone MJ; Ferreira J; Rebella M; Cayota A
Lupus; 2015 Oct; 24(11):1204-9. PubMed ID: 25852050
[TBL] [Abstract][Full Text] [Related]
12. Assessing QT interval in COVID-19 patients:safety of hydroxychloroquine-azithromycin combination regimen.
Bernardini A; Ciconte G; Negro G; Rondine R; Mecarocci V; Viva T; Santini F; de Innocentiis C; Giannelli L; Witkowska E; Locati ET; Castelvecchio S; Marrocco-Trischitta MM; Vicedomini G; Menicanti L; Pappone C
Int J Cardiol; 2021 Feb; 324():242-248. PubMed ID: 32956782
[TBL] [Abstract][Full Text] [Related]
13. Hydroxychloroquine daily dose, hydroxychloroquine blood levels and the risk of flares in patients with systemic lupus erythematosus.
Fasano S; Messiniti V; Iudici M; Coscia MA; Ciccia F
Lupus Sci Med; 2023 Jan; 10(1):. PubMed ID: 36631164
[TBL] [Abstract][Full Text] [Related]
14. Hydroxychloroquine-induced pigmentation in patients with systemic lupus erythematosus: a case-control study.
Jallouli M; Francès C; Piette JC; Huong du LT; Moguelet P; Factor C; Zahr N; Miyara M; Saadoun D; Mathian A; Haroche J; De Gennes C; Leroux G; Chapelon C; Wechsler B; Cacoub P; Amoura Z; Costedoat-Chalumeau N;
JAMA Dermatol; 2013 Aug; 149(8):935-40. PubMed ID: 23824340
[TBL] [Abstract][Full Text] [Related]
15. QTc prolongation among hydroxychloroquine sulphate-treated COVID-19 patients: An observational study.
Fteiha B; Karameh H; Kurd R; Ziff-Werman B; Feldman I; Bnaya A; Einav S; Orlev A; Ben-Chetrit E
Int J Clin Pract; 2021 Mar; 75(3):e13767. PubMed ID: 33063447
[TBL] [Abstract][Full Text] [Related]
16. Hydroxychloroquine use is not associated with QTc length in a large cohort of SLE and RA patients.
Park E; Giles JT; Perez-Recio T; Pina P; Depender C; Gartshteyn Y; Askanase AD; Bathon J; Geraldino-Pardilla L
Arthritis Res Ther; 2021 Oct; 23(1):271. PubMed ID: 34715924
[TBL] [Abstract][Full Text] [Related]
17. Longterm Hydroxychloroquine Therapy and Low-dose Aspirin May Have an Additive Effectiveness in the Primary Prevention of Cardiovascular Events in Patients with Systemic Lupus Erythematosus.
Fasano S; Pierro L; Pantano I; Iudici M; Valentini G
J Rheumatol; 2017 Jul; 44(7):1032-1038. PubMed ID: 28507183
[TBL] [Abstract][Full Text] [Related]
18. Systemic lupus erythematosus and hydroxychloroquine-related acute intermittent porphyria.
Esteve-Valverde E; Tapiz-Reula A; Ruiz D; Alijotas-Reig J
Rheumatol Int; 2020 May; 40(5):777-783. PubMed ID: 31865445
[TBL] [Abstract][Full Text] [Related]
19. The additive effects of hydroxychloroquine to maintenance therapy with standard of care in patients with systemic lupus erythematosus.
Miyagawa I; Nakano K; Nakayamada S; Iwata S; Hanami K; Fukuyo S; Kubo S; Kawabe A; Miyazaki Y; Inoue Y; Ueno M; Ohkubo N; Fujita Y; Tanaka Y
Int J Rheum Dis; 2020 Apr; 23(4):549-558. PubMed ID: 32020727
[TBL] [Abstract][Full Text] [Related]
20. Discontinuation of hydroxychloroquine in older patients with systemic lupus erythematosus: a multicenter retrospective study.
Fernandez-Ruiz R; Bornkamp N; Kim MY; Askanase A; Zezon A; Tseng CE; Belmont HM; Saxena A; Salmon JE; Lockshin M; Buyon JP; Izmirly PM
Arthritis Res Ther; 2020 Aug; 22(1):191. PubMed ID: 32807233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
